GAUSH MEDITECH LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.9 HKD | -4.06% |
|
-5.31% | -50.00% |
| May. 02 | Gaush Meditech Swings to Profit in 2023 | MT |
| Apr. 23 | Gaush Meditech Ltd Announces Change in Joint Company Secretary | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 6,735 | 5,084 | 2,592 | - | - |
| Enterprise Value (EV) 1 | 6,625 | 5,084 | 2,431 | 2,127 | 1,790 |
| P/E ratio | -12.6 x | 29.4 x | 10.8 x | 8.59 x | 7.12 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 5.37 x | 3.62 x | 1.61 x | 1.41 x | 1.24 x |
| EV / Revenue | 5.28 x | 3.62 x | 1.51 x | 1.15 x | 0.86 x |
| EV / EBITDA | 21 x | 15.1 x | 5.56 x | 4.16 x | 3.06 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | 4.58 x | 3.03 x | 1.35 x | 1.17 x | 1 x |
| Nbr of stocks (in thousands) | 147,935 | 147,970 | 147,970 | - | - |
| Reference price 2 | 45.53 | 34.36 | 17.52 | 17.52 | 17.52 |
| Announcement Date | 3/31/23 | 3/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | 1,254 | 1,406 | 1,611 | 1,843 | 2,092 |
| EBITDA 1 | 316.1 | 336.5 | 437.4 | 511 | 584.7 |
| EBIT 1 | 250.3 | 260.5 | 334.4 | 414.6 | 491.9 |
| Operating Margin | 19.96% | 18.52% | 20.76% | 22.5% | 23.51% |
| Earnings before Tax (EBT) 1 | -275.1 | 247.7 | 318 | 402.1 | 484.4 |
| Net income 1 | -349.6 | 173.5 | 239.3 | 302.7 | 364.6 |
| Net margin | -27.89% | 12.34% | 14.86% | 16.43% | 17.43% |
| EPS 2 | -3.610 | 1.170 | 1.620 | 2.040 | 2.460 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 3/31/23 | 3/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 110 | - | 161 | 465 | 803 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -86% | 11% | 13.3% | 14.6% | 15.2% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | 9.930 | 11.40 | 13.00 | 15.00 | 17.50 |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/31/23 | 3/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
17.52
CNY
Average target price
27.79
CNY
Spread / Average Target
+58.64%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -50.00% | 358M | |
| -5.27% | 9.18B | |
| -3.36% | 1.4B | |
| -9.03% | 1.34B | |
| -15.29% | 1.08B | |
| -20.70% | 832M | |
| -1.15% | 463M | |
| +1.81% | 435M | |
| -24.35% | 335M | |
| -3.26% | 211M |
- Stock Market
- Equities
- 2407 Stock
- Financials Gaush Meditech Ltd
